Condition: Advanced Renal Cell Carcinoma · Sponsor: CoImmune
CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy. The active components of CMN-001 are autologous, matured dendritic cells, which have been co-electroporated with both in vitro transcribed (IVT) RNA from an autologous tumor specimen and CD40L RNA. CMN-001 is indicated for treatment of intermediate/poor risk patients with advanced renal cell carcinoma (RCC) in combination with nivolumab plus ipilimumab as first line therapy and in combination with lenvatinib plus everolimus as 2nd line therapy post 1st line failure.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| Emory University | Atlanta, Georgia, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| SUNY Upstate Medical University | Syracuse, New York, United States | — |
| Westchester Medical Center | Valhalla, New York, United States | — |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | — |
| Houston Methodist | Houston, Texas, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| West Virginia University Cancer Institute | Morgantown, West Virginia, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04203901